On February 8, Business Day reported that government is scrambling to reorient its Covid-19 vaccination plans after new evidence regarding the AstraZeneca’s vaccine has emerged.

Wits University released a statement confirming a Financial Times report that preliminary data indicated a two-dose regimen of the Oxford-AstraZeneca vaccine provided “minimal protection” against mild to moderate infection with the B.1.351 variant, also known as 501Y.V2, among SA trial participants.

Other news